Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Orphazyme Stock Is Imploding Today

TheMotleyFool

0 0

Here's Why Orphazyme Stock Is Imploding TodayPhoto, wide shot, wide-angle lens, Brewery, Midday, harsh overhead sunlight, directional sunlightt, photo by Peter Lik: https://img.theapi.app/temp/0cebecb6-c4f6-4c6e-b73e-f375daba8100.png

Shares of Orphazyme (NASDAQ: ORPH), a clinical-stage biopharmaceutical company, are getting hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on Friday.

The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazyme shot up more than 200% in anticipation of a green light that never came.

Image source: Getty Images.

Source Fool.com

Like: 0

ORPH

Share